NCT00126490View on ClinicalTrials.gov

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2012

Study Completion Date

August 31, 2013

Conditions
Recurrent Renal Cell CarcinomaStage IV Renal Cell Cancer
Interventions
BIOLOGICAL

Aldesleukin

Given subcutaneously

BIOLOGICAL

Bevacizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00126490 - Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter